Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity-Reference-Cited by-同舟云学术

Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity

Published:2020-09-29 Issue: Volume:11 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Myers Darienne R.,Abram Clare L.,Wildes David,Belwafa Amira,Welsh Alia M. N.,Schulze Christopher J.,Choy Tiffany J.,Nguyen Tram,Omaque Neil,Hu Yongmei,Singh Mallika,Hansen Rich,Goldsmith Mark A.,Quintana Elsa,Smith Jacqueline A. M.,Lowell Clifford A.

Funder

National Institutes of Health

Cancer Research Coordinating Committee

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference58 articles.

1. fundamental mechanisms of immune checkpoint blockade therapy;Wei;Cancer Discov.,2018

2. Macrophages: the road less traveled, changing anticancer therapy;Guerriero;Trends Mol Med.,2018

3. Molecular pathways: activating t cells after cancer cell phagocytosis from blockade of CD47 “don't eat me” signals;McCracken;Clin Cancer Res.,2015

4. Cancer immunotherapy targeting the CD47/SIRPalpha axis;Weiskopf;Eur J Cancer.,2017

5. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma;Chao;Cell.,2010

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Toxoplasma secreted effector TgWIP modulates dendritic cell motility by activating host tyrosine phosphatases Shp1 and Shp2;Cellular and Molecular Life Sciences;2024-07-09

2. Podocyte SIRPα reduction aggravates lupus nephritis via promoting T cell inflammatory responses;Cell Reports;2024-05

3. Signaling-biophysical modeling unravels mechanistic control of red blood cell phagocytosis by macrophages in sickle cell disease;PNAS Nexus;2024-01-20

4. Protein tyrosine phosphatases as emerging targets for cancer immunotherapy;British Journal of Pharmacology;2024-01-17

5. Small molecule inhibitors for cancer immunotherapy and associated biomarkers – the current status;Frontiers in Immunology;2023-10-31